ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

COSENTYX
Arthritis/rheumatic disorders
Psoriasis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

COSENTYX Rx

Generic Name and Formulations:
Secukinumab 150mg/mL; soln for SC inj; and lyophilized pwd for SC inj after reconstitution; preservative-free.

Company:
Novartis Pharmaceuticals Corp

Therapeutic Use:

Indications for COSENTYX:

Active psoriatic arthritis or ankylosing spondylitis in adults.

Adult:

Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). ≥18yrs: Psoriatic arthritis with coexistent plaque psoriasis: 300mg (given as two 150mg SC injections) at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. Other psoriatic arthritis (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks; consider a 300mg dose if psoriatic arthritis continues. Cosentyx may be administered with or without MTX. Ankylosing spondylitis (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks.

Children:

<18yrs: not evaluated.

Warnings/Precautions:

Increased risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. Evaluate for TB infection prior to initiating; monitor for active TB during and after therapy. Patients with active TB infection: do not start. History of latent or active TB; consider anti-TB therapy prior to initiation. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy (Cat.B). Nursing mothers.

Interactions:

Concomitant live vaccines: not recommended. Non-live vaccines: may get suboptimal response. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.

Pharmacological Class:

Interleukin-17A antagonist.

Adverse Reactions:

Nasopharyngitis, diarrhea, upper respiratory tract infection, rhinitis, oral herpes, pharyngitis, urticaria, rhinorrhea; inflammatory bowel disease, hypersensitivity reactions, other serious infections.

Generic Availability:

NO

How Supplied:

Single-use Sensoready pen—1, 2; Single-use prefilled syringe—1, 2; Single-use vial—1

Indications for COSENTYX:

Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Adult:

Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). ≥18yrs: 300mg (given as two 150mg SC injections) at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. For some patients, 150mg dose may be acceptable.

Children:

<18yrs: not evaluated.

Warnings/Precautions:

Increased risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. Evaluate for TB infection prior to initiating; monitor for active TB during and after therapy. Patients with active TB infection: do not start. History of latent or active TB; consider anti-TB therapy prior to initiation. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy (Cat.B). Nursing mothers.

Interactions:

Concomitant live vaccines: not recommended. Non-live vaccines: may get suboptimal response. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.

Pharmacological Class:

Interleukin-17A antagonist.

Adverse Reactions:

Nasopharyngitis, diarrhea, upper respiratory tract infection, rhinitis, oral herpes, pharyngitis, urticaria, rhinorrhea; inflammatory bowel disease, hypersensitivity reactions, other serious infections.

Generic Availability:

NO

How Supplied:

Single-use Sensoready pen—1, 2; Single-use prefilled syringe—1, 2; Single-use vial—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs